Epilepsy accounted for a 3.3% share of the global clinical trials within the Central Nervous System therapy area in 2020, registering a decrease of 0.1% when compared with the last ten-year average of 3.4% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Epilepsy
Industry sponsored trials held a 59.8% share of all the clinical trials for Epilepsy indication in 2020, registering an increase of 11.3% when compared with the ten-year average of 48.5%. Non-industry sponsored trials accounted for a 40.2% share in 2020, marking a decrease of 11.3% over the ten-year average of 51.5%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Epilepsy trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Epilepsy trials, accounting for a 58.5% share in 2020, when compared with the five-year average of 50.7% and ten-year average of 49.3%.
Europe was at the second position with a 27.7% share in 2020, over the five-year average of 34.6% and ten-year average of 40.2%, followed by North America with a 26.2% share in 2020, as against five-year and ten-year averages of 37.9% and 39.3% respectively.
Middle East and Africa stood fourth with a 1.5% share in 2020, compared with the five-year average of 8.1% and ten-year average of 8.7%, followed by South and Central America with a 0.0% share in 2020, over five-year and ten-year averages of 3.8% and 5.9% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Epilepsy trials, accounting for a 26.2% share in 2020, as against the five-year average of 18.1% and ten-year average of 13.1%.
The US held a 26.2% share in 2020, over the five-year average of 37.0% and ten-year average of 37.5%, followed by Russia with a 16.9% share in 2020, compared with the five-year and ten-year averages of 8.1% and 12.4% respectively.
Australia held a 10.8% share in 2020, as against the five-year average of 17.3% and ten-year average of 13.2%.
Thailand held a 7.7% share in 2020, over the five-year and ten-year averages of 4.4% and 6.7% respectively.
Top regions of non-industry sponsored Epilepsy trials
Asia-Pacific was the top region for non-industry sponsored Epilepsy trials, accounting for a 50.0% share in 2020 when compared with the five-year average of 45.6% and ten-year average of 36.7%.
Middle East and Africa was at the second position with a 20.8% share in 2020, over the five-year and ten-year averages of 19.7% and 21.3% respectively, followed by North America with a 14.6% share in 2020, as against the five-year average of 22.0% and ten-year average of 25.4%.
Europe stood at the fourth position with a 14.6% share in 2020, compared with the five-year average of 13.9% and ten-year average of 17.5%, followed by South and Central America with a 0.0% share in 2020, over the five-year and ten-year averages of 2.2% and 1.7% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Epilepsy trials, accounting for a 20.8% share in 2020, as against the five-year average of 10.7% and ten-year average of 9.2%.
Iran held an 18.8% share in 2020, over the five-year average of 13.7% and ten-year average of 16.5%, followed by India with a 16.7% share, compared with the five-year and ten-year averages of 18.1% and 13.3% respectively.
The US held a 14.6% share in 2020, as against the five-year average of 17.3% and ten-year average of 21.7%.
Thailand held a 6.3% share in 2020, over the five-year average of 2.9% and ten-year average of 1.8%.
Phase I trials lead industry sponsored clinical trials for Epilepsy in 2020
Phase I trials held a 61.8% share of industry sponsored clinical trials for Epilepsy in 2020, over the five-year average of 43.6% and ten-year average of 41.6%.
Phase IV trials held a 14.5% share in 2020, as against the five-year average of 14.6% and ten-year average of 17.4%. Phase II trials held an 11.8% share in 2020, compared with the five-year and ten-year averages of 20.7% and 16.0% respectively.
Phase III trials held an 11.8% share in 2020, over the five-year average of 21.0% and ten-year average of 25.0%.
Phase II trials lead non-industry sponsored clinical trials for Epilepsy in 2020
Phase II trials held a 43.1% share of non-industry sponsored clinical trials for Epilepsy in 2020, over the five-year average of 41.8% and ten-year average of 45.4%.
Phase IV trials held a 27.5% share in 2020, as against the five-year average of 29.0% and ten-year average of 28.3%. Phase III trials held a 15.7% share, compared with the five-year and ten-year averages of 21.1% and 18.5% respectively.
Phase I trials held a 13.7% share in 2020, over the five-year average of 8.1% and ten-year average of 7.8%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
